The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") extraordinary general meeting held today, on 30 September 2024, in Stockholm.
Determination of the number of board members
The extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that the number of members of the board of directors to be elected by the general meeting shall be three (3) without alternate members of the board of directors.
Election and removal of board members
The extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that Mark E. Hensley, Yoshikazu Aoki and Masaya Eto are elected as new members of the board of directors for the period until the end of the next annual general meeting, that Mark E. Hensley is elected as chairman of the board of directors for the period until the end of the next annual general meeting and that Elmar Schnee, Elisabeth Björk, Frederick Driscoll, Hilde Furberg, Diane Parks and Henrik Stenqvist are removed from their positions as members of the board of directors.
Determination of fees to the board members
The extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that no fees shall be paid to the members of the board of directors.
Resolution that the principles for appointing the nomination committee shall no longer apply after the delisting of Calliditas' shares from Nasdaq Stockholm
The extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that the principles and the instructions for the appointment of the members of the nomination committee, which was adopted by the extraordinary general meeting 2017, shall no longer apply when Calliditas' shares are delisted from Nasdaq Stockholm.
Resolution that the guidelines on remuneration to group management and board members shall no longer apply after the delisting of Calliditas' shares from Nasdaq Stockholm
The extraordinary general meeting resolved, in accordance with Asahi Kasei Corporation's proposal, that the guidelines on remuneration to group management and board members, which was adopted by the annual general meeting 2024, shall no longer apply when Calliditas' shares are delisted from Nasdaq Stockholm.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability
E-mail: asa.hillsten@calliditas.com
Telephone: + 46 76 403 35 43
The information was submitted for publication, through the agency of the contact person set out above, at 14:30 CEST on 30 September 2024.
About Calliditas
Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX). Visit Calliditas.com for further information.